These are articles reviewing the extensive literature on mesothelioma cancer in an attempt to offer current answers on the cause, diagnosis and treatment of malignant mesothelioma. While they are an excellent way to start an inquiry, they may not answer more specific questions, pertinent to the individual case.
Need synopsis. - Ind Health. 2010 Dec 16. [Epub ahead of print]
Need synopsis. - Ann Thorac Surg. 2010 Sep;90(3):949-56; discussion 956.
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.
In the past, diffuse malignant peritoneal mesothelioma (DMPM) was regarded as a preterminal condition. - Ann Oncol. 2006 Nov 27; [Epub ahead of print]
The incidence of malignant mesothelioma continues to increase, but the disease remains difficult to detect early and treat effectively. - Cancer Control. 2006 Oct;13(4):255-63
The author reviewed 1,517 human malignant mesothelioma cases from 1975 through August 2000. These mesothelioma cases were definite or probable in diagnostic certainty. Sources of these cases varied including asbestos insulation workers, UNARCO workers, Cancer and Leukemia B mesothelioma panel cases and random cases. - Ind Health 2001 Apr;39(2):183-5
Malignant pleural mesothelioma (MPM) is a rare tumor that predominantly afflicts men over 50 years of age. Nearly 3000 MPMs are reported annually in the United States with the incidence expected to rise into the new millenium. - World J Surg 2001 Feb;25(2):210-7
This review will discuss the roles of chemotherapy, radiotherapy, mesothelioma surgery, and combined modality approaches in the treatment of pleural mesothelioma, as well as scientific advances made in the past decade that have led to the development of experimental techniques, such as photodynamic therapy, immunotherapy, and gene therapy, that are currently undergoing human clinical trials. - Chest 1999 Aug;116(2):504-20
Dr. Lary A. Robinson, from the H. Lee Moffitt Cancer Center and Research Institute, shares with Jim Early the center's strong interest and experience in the evaluation and treatment of malignant pleural mesothelioma of all stages.